Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Judge Boasberg says the court should not "prematurely intrude" on FDA resolution of two factual issues: the approvability of Mylan's atorvastatin ANDA and any generic marketing exclusivity determination involving Ranbaxy.

Related Content

FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
Mylan vs. FDA (And Ranbaxy): Diovan Exclusivity Forfeiture Edition
Lipitor Generics Watch: FDA Has Yet To Approve ANDA For The World's #1 Drug
Mylan Weighs "Big Bang" Or "Phased" Products Rollout In India; Significant Workforce Additions Planned
FDA Import Alert Lifted, Apotex Says; Will Lipitor ANDA Approvals Be Far Behind?
Lipitor Generics: Judge Questions Mylan's Right To Sue Over Marketing Exclusivity
Lipitor Generics: FDA Says Mylan Has No Standing To Sue (Until June 28?)
Mylan Lawsuit Seeks To Force FDA's Hand On Lipitor Generics
Mylan Lawsuit Seeks To Force FDA's Hand On Lipitor Generics
Lipitor Generic Bottleneck Needs To Be Cleared "Now," Senators Tells FDA





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts